Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

16.45 -0.93 (-5.35%)
Delayed Quote Updated: 1:52 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
3 Unprofitable Stocks Walking a Fine Line
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding... 
Via StockStory
News headline image
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Let’s dig into the relative performance of NeoGenomics (NASDAQ:NEO) and its peers as we unravel the now-completed Q4 testing & diagnostics services earnings ... 
Via StockStory
News headline image
3 Cash-Burning Stocks We Think Twice About
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh... 
Via StockStory
Topics Economy
NeoGenomics Inc (NASDAQ:NEO) Beats Q4 Earnings Estimates and Provides 2026 Guidance ↗
Via Chartmill
News headline image
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Reasons to Avoid NEO and 1 Stock to Buy Instead
What a fantastic six months it’s been for NeoGenomics. Shares of the company have skyrocketed 48.3%, hitting $9.94. This was partly thanks to its solid quarterly results, and the performance may have... 
Via StockStory
News headline image
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
From NeoGenomics, Inc.
Via Business Wire
News headline image
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call
NeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s... 
Via StockStory
Topics Earnings
News headline image
Why NeoGenomics (NEO) Shares Are Falling Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a... 
Via StockStory
Topics Artificial Intelligence
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company... 
Via StockStory
News headline image
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript ↗
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company... 
Via StockStory
Topics Earnings
News headline image
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday before the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
From NeoGenomics, Inc.
Via Business Wire
News headline image
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Cash-Burning Stocks with Warning Signs
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
Topics Electric Vehicles
News headline image
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Russell 2000 Stocks We Think Twice About
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
3 Stocks Under $50 We Steer Clear Of
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.